EULAR Highlights. 2 new JAKs presented more RA data. Upadacitinib and Filgotinib. Safety of JAKs in meta-analysis -no new safety signals. Tofacitinib use in Corrona = TNFI except slightly more shingles. 7yr Baricitinib data good - no VTE in LTE #EULAR2019 @RheumNow